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Abstract
Clinical trials indicate that amifostine may confer protection on
various normal tissues without attenuating anti-tumor response. When
administered prior to chemotherapy or radiotherapy, it may provide a
broad spectrum of cytoprotection including against alkylating drugs.
The mechanism of protection resides in the metabolism at normal
tissue site by membrane-bound alkaline phosphatase. Toxicity of this
drug is moderate with hypotension, nausea and vomiting, and hypo-
calcemia being observed. We report a phase II study using amifostine
as a protective drug against high-dose cyclophosphamide (HDCY) (7
g/m2), used to mobilize peripheral blood progenitor cells (PBPC) and
to reduce tumor burden. We enrolled 29 patients, 22 (75.9%) affected
by aggressive and 7 (24.1%) by indolent non-Hodgkin’s lymphoma
(NHL), who were submitted to 58 infusions of amifostine and com-
pared them with a historical group (33 patients) affected by aggressive
NHL and treated with VACOP-B followed by HDCY. The most
important results in favor of amifostine were the reduction of intensity
of cardiac, pulmonary and hepatic toxicity, and a significant reduction
of frequency and severity of mucositis (P = 0.04). None of the 29
patients died in the protected group, while in the historical group 2/33
patients died because of cardiac or pulmonary toxicity and 2 patients
stopped therapy due to toxicity. Amifostine did not prevent the
aplastic phase following HDCY. PBPC collection and hematological
recovery were adequate in both groups. The number of CFU-GM
(colony-forming units-granulocyte/macrophage) colonies and mono-
nuclear cells in the apheresis products was significantly higher in the
amifostine group (P = 0.02 and 0.01, respectively). Side effects were
mild and easily controlled. We conclude that amifostine protection
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Introduction
The two major obstacles in an effective
cancer therapy are drug resistance and toxic-
ity to normal organs which prevent the use of
optimal doses and schedules. A broad-spec-
trum selective cytoprotective agent which
improves patient tolerance could allow the
delivery of higher cumulative doses of che-
motherapy and would improve life quality, a
useful adjunct in cancer medicine.
Amifostine is a pro-drug that is dephos-
phorylated in the tissue by alkaline phos-
phatase to a free thiol, the active metabolite
(WR-1065) (1-3). It acts as a potent scaven-
ger of oxygen free radicals induced by
ionising radiation and certain types of che-
motherapy (1-3). The mechanism of protec-
tion is based on physiological differences
between the two tissue types and on differ-
ential uptake of amifostine in normal and
tumor tissue (4). Cytoprotection has been
found to correlate only with intracellular
levels of the thiol metabolite WR-1065 (2).
Further reaction with other intracellular thiol
groups forms either its symmetrical disul-
fide or mixed disulfides. The hydrogen atom
donation from these metabolites facilitates
direct chemical repair at sites of DNA dam-
age. Amifostine selectively protects a broad
range of normal tissues against the toxicity
associated with chemotherapy and radiation
without affecting the anti-tumor activity of
the agents (3,5-7). Many experiments have
demonstrated that there is no evidence of
attenuation of the anti-tumor effect when
amifostine protection is used (1,8,9). Pre-
incubation with amifostine or WR-1065 en-
hanced the colony-forming capacity of the
bone marrow progenitors, increasing recov-
ery of CFU-GEMM (colony-forming units-
granulocyte/erythroid/macrophage/mega-
karyocytic) and BFU-E (burst-forming units-
erythroid) up to seven-fold (1,10). Signifi-
cant side effects related to amifostine in-
clude nausea, vomiting, and hypotension
(1,11,12). An additional side effect is tran-
sient hypocalcemia because of inhibition of
the release of parathyroid hormone (1,13).
The most clinically significant and dose-
limiting toxicity is hypotension generally at
the end of the infusion and quickly revers-
ible by discontinuation of the drug (1,11,12).
The precise mechanism of hypotension is
unclear but it seems to be related to a direct
vasodilator (14).
In view of these considerations, we re-
port here a phase II study using amifostine
protection in patients treated with high-dose
alkylating agent (cyclophosphamide (CY), 7
g/m2), in order to mobilize peripheral blood
progenitor cells (PBPC) and to reduce the
tumor mass in patients affected by non-
Hodgkin’s lymphomas (NHL). The objec-
tive of the present investigation was to study
the feasibility, side effects, and the extent of
tissue and organ protection by amifostine.
Patients and Methods
From February 1997 to June 1999, 29
patients (14 males and 15 females), median
age 46 years (range 18-56), 22 (75.9%) af-
fected by aggressive NHL and 7 (24.1%) by
indolent NHL, were enrolled in the study.
Seven of the 29 patients (24.1%) were in
complete remission, 15 (51.8%) in partial
remission, and 7 (24.1%) were non-respond-
ers. Twelve (41.3%) patients had previously
received one line of chemotherapy; 11
(37.9%), two lines, and 6 (20.8%), three or
more (median treatment, 2 chemotherapy
lines; range 1-5). The 29 patients were sub-
mitted to a total of 58 CY infusions protected
by amifostine during the progenitor cell mo-
bilization procedure (15). The total CY dose
(7 g/m2) was divided into 5 equal infusions
(1.4 g/m2). Amifostine was infused 30 min
before the first and 5th CY infusion, as shown
in Table 1. Amifostine was infused for 15
min and CY was administered 15 min after
the end of amifostine infusion. Urinary pH
was determined before amifostine infusion
and it had to be ³7.0. Patients presenting pH
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<7 were treated with sodium bicarbonate in
order to achieve the ideal pH before infu-
sion. Twenty-seven (93.1%) patients were
protected with 740 mg/m2 amifostine twice,
while only two (6.9%) patients received 910
mg/m2 in each of the two infusions. Echocar-
diography was used as the criterion for the
procedure. Patients presenting ventricular
ejection fraction below 60% did not undergo
therapy and patients presenting limit values
were submitted to scintigraphy prior to high-
dose cyclophosphamide (HDCY).
We analyzed neutrophil and platelet recov-
ery, median number and range of leukaphere-
ses, total mononuclear cells, CD34+ cells and
CFU-GM colonies obtained from leukapheresis
products. CD34 cells were quantified using a
modification of the method described by
Sutherland et al. (16). In this modification, the
CD14/FITC antibody was used instead of CD45
to exclude contamination with myeloid/mono-
cytic cells of the CD34/PE-positive popula-
tion defined as CD14 negative and presenting
a low relative granularity or internal complex-
ity. The in vitro colony-forming assay was
performed by plating total unstimulated pe-
ripheral blood leukocytes obtained after red
blood cell sedimentation in the presence of
33% Emagel, as described elsewhere (17).
The total number of CD34+ cells (x 106/kg)
and CFU-GM (x 104/kg) was determined by
multiplying their frequency per ml by the total
volume of cryopreserved cell suspension and
dividing by body weight. We compared these
results with a historical non-protected group
consisting of 40 patients affected by aggres-
sive NHL. Before receiving HDCY, these pa-
tients were treated with a median number of 8
courses of VACOP-B (18), and 33 patients
underwent HDCY therapy followed by granu-
locyte colony-stimulating factor (G-CSF) in
order to collect PBPC and reduce the tumor
burden. Seven patients did not undergo HDCY
due to early death or progression of the dis-
ease. Table 2 shows the patients’ characteris-
tics, and Table 1 shows the time schedule for
HDCY administration.
Table 1 - Time schedule for the administration of
high-dose cyclophosphamide (7 g/m2) and amifos-
tine protection.
Hyperhydration plus furosemide and acetazola-
mide was used as previous support therapy. The
standard dose of amifostine was 740 mg/m2. A
dose of 910 mg/m2 was used in high-risk patients.
Time (h) Cyclophosphamide Uromitexan
Amifostine (15 min)
0 1.4 g (m2)-1 h-1
1 1.5 g (m2)-1 h-1
3 1.4 g (m2)-1 h-1
4 1.5 g (m2)-1 h-1
6 1.4 g (m2)-1 h-1
7 1.5 g (m2)-1 h-1
9 1.4 g (m2)-1 h-1
10 1.5 g (m2)-1 h-1
Amifostine (15 min)
12 1.4 g (m2)-1 h-1
13 1.5 g (m2)-1 h-1




Number of patients 29
Age (year), median (range) 46 (18-56)
Male/female 14/15
Histology
Aggressive non-Hodgkin’s lymphoma 22 75.9
Indolent non-Hodgkin’s lymphoma 7 24.1
Disease status
Partial remission 15 51.8





3 or more 6 20.8
Median (range) 2 (1-5)
Historical group
Number of patients at diagnosis 40
Age (year), median (range) 51 (20-60)
Male/female 25/15
Histology - aggressive non-Hodgkin’s lymphoma 40 100
HDCY (after 8 cycles of VACOP-B) 33 82.5
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amifostine infusion. HDCY toxicity was
determined according to the World Health
Organization (WHO). Informed consent
was obtained from the patients according
to institution regulations.
Statistical analysis
Analysis was based on data for the ami-
fostine group versus the historical non-pro-
tected group. Our main objective was to
compare the theoretical benefits of amifos-
tine cytoprotection. All data were analyzed
with descriptive statistical methods and the
proportions of patients within each group of
characteristics and outcome, including short-
term side effects, were compared by the
Fisher test. In addition, comparisons of the
continuous variables were performed by the
Mann-Whitney test, with the level of signif-
icance set at P<0.05.
Results
Amifostine-protected group
The most important symptoms related to
amifostine infusions were nausea and vomit-
ing in 12/58 patients (20.6%), hypotension
in 26/58 (44.8%), hypocalcemia in 4/58
(6.9%), and flu-like symptoms in 2/58 (3.5%).
All symptoms were mild and easily con-
trolled by the use of methylprednisolone
(125 mg, iv) or calcium gluconate (100-300
mg, iv) when necessary. Twenty-three pa-
tients (79%) presented fever of undetermined
origin which was controlled with antibiotics.
One patient presented grade 1 mucositis,
two patients presented line contamination
by Staphylococcus aureus, controlled with
vancomycin, and one patient died due to
progressive disease. Two patients showed
cardiac toxicity, grade 1 and grade 2, respec-
tively. No severe toxicity (grades 3 and 4)
was observed in liver, kidney or lung (Table
3). Regarding hypotension, Figure 1 shows a
























-5 0 15 30 45 60 120
Time (min)
Figure 1 - Blood pressure rate
following amifostine infusion.
Table 3 - Toxicity related to HDCY therapy in patients protected or not with amifostine
(WHO classification).
HDCY, High-dose cyclophosphamide; NS, nonsignificant. Data were analyzed by the
Fisher exact test.
Tissue/organ HDCY + amifostine HDCY P
grades - WHO grades - WHO
0 1 2 3 4 Total 0 1 2 3 4 Total
Heart 27 1 1 - - 29 31 - - 1 1 33 NS
Liver 28 - 1 - - 29 29 2 1 1 - 33 NS
Mucositis 28 1 - - - 29 26 4 2 1 - 33 0.04
Lung 29 - - - - 29 32 - - - 1 33 NS
Kidney 29 - - - - 29 30 - 1 1 1 33 NS
Side effects related to amifostine and
evaluation of toxicity
The most important short-term side
effects of amifostine were the presence of
nausea and/or vomiting, hypotension, hy-
pocalcemia and flu-like symptoms. Blood
pressure was determined each 5 min during
amifostine infusion. The infusion was re-
duced when the systolic blood pressure de-
creased more than 10% or if it decreased
>20 mmHg over a period of 5 min or if
symptomatic hypotension was present. Se-
rum calcium levels were determined be-
fore, during and after amifostine infusion
and at 24-h intervals for 4 days. The side
effects were treated using methylpredniso-
lone and/or intravenous calcium injections.
Thirteen patients were treated preventively
with dexamethasone (20 mg, twice a day),
intravenous calcium injection and glanis-
entron (3 mg, iv) about 90 min before
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reduction of about 7.5%), 15 to 30 min after
the beginning of amifostine infusion. No
infusions were stopped because of hypoten-
sion. Figure 2 shows a slight reduction in
serum calcium 72 h after amifostine infusion
(median reduction of about 6%). The me-
dian day for neutrophil counts above 0.5 x
109/l was the 12th (10th-18th), for counts
>1.0 x 109/l it was the 13th (10th-19th), for
platelets >20 x 109/l it was the 11th (9th-
25th) and for platelets >50 x 109/l it was the
12th (9th-30th). The median number of
aphereses was 2 (range 1-9), the median
total mononuclear cell count was 8.26 x 108/
kg (3.3-29.9), the median count of CD34+
cells was 12.35 x 106/kg (2.0-74.1), and the
median number of CFU-GM colonies was
114.14 x 104/kg (27.7-680.0).
Historical group
Forty patients with aggressive NHL were
enrolled in the study and received a median of
8 cycles of VACOP-B as front line therapy.
Seven patients did not undergo HDCY due to
progression of the disease or early death. Thirty-
three patients underwent HDCY without ami-
fostine protection. Four patients did not un-
dergo autologous bone marrow transplanta-
tion due to severe toxicity after HDCY. Two
patients died, one due to cardiac failure and
one due to pulmonary fibrosis. In addition,
two patients had severe liver and kidney toxic-
ity, grades 3 and 4, respectively. Table 3 shows
the toxicity related to HDCY in this group. The
median day for neutrophil counts above 0.5 x
109/l was the 10th (7th-17th), for counts >1.0
x 109/l it was the 10th (8th-21st), for platelets
>20 x 109/l it was the 11th (7th-27th), and for
platelets >50 x 109/l it was the 13th (8th-43th).
Patients underwent leukapheresis on median
day 12 (range 10-16). A median of 3 aphereses
(range 1-7) was performed. The median num-
ber of harvested mononuclear cells was 6.10 x
108/kg (range 0.14-23.9), the median number
of CD34+ cells was 17.08 x 106/kg (range
2.87-103.0), and the median number of CFU-
GM colonies was 45.0 x 104/kg (range 1.16-
681.0).
Comparison between two groups
Table 3 shows non-hematologic toxicity
according to WHO grades in both groups
analyzed and its statistical significance. Mu-
cositis toxicity was more frequent in the
non-protected group (P = 0.04). However,
the most important clinical differences were
observed in the severity of toxicity. In the
historical group we observed severe cardiac,
renal, hepatic and pulmonary toxicity, in-
cluding two lethal cases. No differences in
hematologic toxicity were observed between
groups. Neutrophil recovery was faster in
the historical group (P<0.001), while no dif-
ference was observed between groups in
terms of platelet recovery. PBPC collections
were similar in both groups in terms of CD34+
cell numbers. However, the number of CFU-
GM colonies and mononuclear cells was
significantly higher in the amifostine-pro-
tected group (P = 0.02 and P = 0.01, respec-
tively). The median number of aphereses
was 3 (1-9) in the historical group and 2 (1-
7) in the amifostine group, showing a trend
in favor of the amifostine group (P = 0.06).
Table 4 shows the biological data concern-
ing PBPC mobilization in both groups.
Discussion
This phase II study using amifostine as a





























Pre 0 12 24 48 72
Time (h)





Braz J Med Biol Res 33(7) 2000
C.A. De Souza et al.
of 7 g/m2 of cyclophosphamide indicates
that amifostine and its free thiol derivative
may confer protection on most tissues and
organs against HDCY. Amifostine was able
to prevent severe and lethal cardiac and pul-
monary toxicity, and to reduce the frequency
and severity of renal toxicity and mucositis.
Many antineoplastic drugs have been stud-
ied using cytoprotective agents including the
anthracyclines, daunorubicin and doxorubi-
cin, the anthracenedione, mitoxanthrone,
paclitaxel, diaziquone, cisplatin, and thiotepa
(1). However, few studies have used high-
dose alkylating drug protection in bone mar-
row transplantation and/or mobilization pro-
cedures (19). A one-way crossover phase II
trial was conducted in order to evaluate the
protective effect of amifostine against cyclo-
phosphamide-induced hematologic toxicity
(20). The patients received 1500 mg/m2 of
CY alone, protected with 740 mg/m2 of am-
ifostine. Amifostine significantly attenuated
the neutrophil nadir (P<0.001) and reduced
the duration of neutropenia grade 4
(P£0.016). However, the CY dosage was
much lower than those used in our study, and
organic toxicity was not evaluated. On the
other hand, our study using 7 g/m2 CY did
not present any advantage of hematologic
protection in terms of hematologic recovery
compared with the historical group. The num-
ber of CFU-GM and mononuclear cells, how-
ever, was significantly higher in spite of
more chemotherapy cycles previously ap-
plied to most of the protected patients, sug-
gesting amifostine protection of progenitor
cells. In addition, we observed a trend in
favor of the amifostine group in terms of
number of aphereses, which was lower in the
protected group (P = 0.06). An important
difference in favor of amifostine protection
was the reduction of severe non-hemato-
logic toxicity, particularly renal, hepatic, pul-
monary and cardiac toxicity. Besides, mu-
cositis was observed only in one patient
(grade 1) and no treatment-related death was
observed in the protected group. The choice
of the protective dosage of amifostine used
in this study was defined previously (21,22),
ranging from 740 to 910 mg/m2, and seems
to be safe and to have low side effects. The
side effects related to amifostine were mild
and easily controlled. In 58 infusions, the
most important side effects were nausea and
vomiting, hypotension, and clinical and/or
laboratory hypocalcemia. Nausea and vom-
iting should be treated with careful fluid
balance monitoring, beginning before infu-
sion and using anti-emetic medication prior
to and in conjunction with amifostine. Hy-
potension may be controlled using hydration
prior to amifostine infusion, maintaining
Table 4 - Biological data concerning the mobilization procedure using HDCY plus G-CSF in the amifostine-
protected group and a historical non-protected group.
Data are reported as median (range) and were analyzed by the Mann-Whitney test. NS, Nonsignificant.
Amifostine group Historical group P
N = 29 N = 33
Days - neutrophils >0.5 x 109/l 12 (10-18) 10 (7-17) <0.0001
Days - neutrophils >1.0 x 109/l 13 (10-19) 10 (8-21) <0.0001
Days - platelets >20 x 109/l 11 (9-25) 11 (7-27) NS
Days - platelets >50 x 109/l 12 (9-30) 13 (8-43) NS
Number of aphereses median (range) 2 (1-9) 3 (1-7) 0.06
Mononuclear cells x 108/kg median (range) 8.26 (3.3-29.9) 6.10 (0.14-23.9) 0.01
CD34+ cells x 106/kg median (range) 12.35 (2.0-74.1) 17.08 (2.87-103.0) NS
CFU-GM x 104/kg median (range) 114.14 (27.7-680.0) 45.0 (1.16-681.0) 0.02
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patients in the supine position, and control-
ling their blood pressure every 5 min. Cal-
cium level was the only parameter that needed
daily control for four to five days after ami-
fostine infusion.
The administration of amifostine as a
cytoprotective drug against HDCY seems to
be simple and to have an acceptable toxicity
profile. There was no evidence of attenua-
tion of the anti-tumor effects in many experi-
ments performed (8,9). Careful patient se-
lection, prophylactic therapy before amifos-
tine and monitoring blood pressure during
infusion can minimize some of the associ-
ated side effects. Further investigation of the
cytoprotective effects of amifostine with
high-dose alkylating chemotherapy, particu-
larly HDCY in combination with growth
factors, and its utility in the therapy and
progenitor cell mobilization procedure is re-
quired to confirm the importance of this
procedure for tissue and organ protection.
Randomized trials, including cost-benefits
analysis, are needed to demonstrate the clini-
cal usefulness of amifostine in HDCY treat-
ment.
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